- Market Capitalization, $K 10,541
- Shares Outstanding, K 2,100
- Annual Sales, $ 27,470 K
- Annual Income, $ -20,370 K
- 60-Month Beta 2.53
- Price/Sales 0.28
- Price/Cash Flow N/A
- Price/Book 1.47
|Period||Period Low||Period High||Performance|
| || |
+0.59 (+13.32%)since 01/21/20
| || |
+0.55 (+12.30%)since 11/21/19
| || |
-2.48 (-33.07%)since 02/21/19
Cancer Genetics, Inc. (Nasdaq: CGIX) ("Cancer Genetics" or the "Company"), a leader in drug discovery and preclinical oncology and immuno-oncology services, today published a letter to shareholders from...
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board...
A new study by scientists from India, USA, and UK has presented clinical evidence for an innovative test that can detect clusters of cancer cells in the blood of asymptomatic individuals as a non-invasive...
- The new study by Datar Cancer Genetics [https://datarpgx.com/] has used a revolutionary new method that detects clusters of tumor cells circulating in the bloodstream and helps in early detection of...
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the third quarter...
Note Payment Received from Interpace Diagnostics Group, Inc.
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding...
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...
LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ --